Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

University of Texas Medical Branch and GenoLogics to Develop a Biomedical Informatics Solution

Published: Tuesday, August 19, 2008
Last Updated: Tuesday, August 19, 2008
Bookmark and Share
The Sealy Center for Molecular Medicine at the UTMB has selected GenoLogics to collaborate on developing an integrated biomedical software solution.

GenoLogics has announced that the Sealy Center for Molecular Medicine at the University of Texas Medical Branch at Galveston (UTMB) has selected GenoLogics to collaborate on developing an integrated biomedical software solution.

The Sealy Center for Molecular Medicine (SCMM) is an interdisciplinary research center at UTMB and is part of the newly formed Institute for Translational Sciences (ITS). The mission of the SCMM is to serve as a focal interface between clinical and basic scientists, addressing UTMB’s strategic plan for personalized medicine.

“The GenoLogics vision to help clients conduct translational research by developing informatics solutions designed for this purpose was completely aligned with the center’s strategic plan to connect our clinical and basic research areas,” said Dr. Allan Brasier, Director, Sealy Center for Molecular Medicine at UTMB.

“In order to enable our goal for personalized medicine, we decided to collaborate with GenoLogics to deploy a biomedical solution that will begin with user-friendly software to efficiently and effectively manage our biospecimens. Investing in a biomedical informatics solution that can also connect to our research data is going to assist the Center with attracting future funding such as the Clinical and Translational Science Awards.”

The Sealy Center for Molecular Medicine is focused on understanding cell stress response pathways using high-throughput systems-based approaches. The biomarkers program is developing new tools to study and classify human diseases at a molecular level, allowing the prediction of individual susceptibility to disease. This research program in personalized medicine will allow the center to make better diagnostics for common medical diseases such as asthma, cancer, diabetes and degenerative diseases.

“In order to validate our biomarkers for common diseases, we needed to exchange information from clinical to research domains, “ said Dr. Kevin Rosenblatt, Director for Biomarker Discovery, Sealy Center for Molecular Medicine. “This can only be done with a biomedical informatics solution that not only tracks our biospecimens, but also the clinical annotations and then connects to the data being generated in our research labs. The GenoLogics Biomedical Informatics solution will have this unique capability to bring it all together in a single platform.”

GenoLogics launched its Biomedical Informatics software solution to address the needs of translational research initiatives. The solution allows clients to track prospective studies, collect patient data at remote sites, provide biospecimen and clinical annotations management and facilitate researchers querying on clinical information and requesting samples. The solution is comprised of five integrated products: BioVault for biospecimen management; BioChronicle for clinical annotations management; BioQuest to enable Web access; BioSphere for study management; and BioSource for electronic patient questionnaires.

“As we develop our new biomedical informatics product suite, it’s important to gain the real-world experience of leading organizations such as the Sealy Center for Molecular Medicine,” says James DeGreef, VP Market Strategy for GenoLogics.

“Their input into the design and development of the biospecimen and clinical annotations products will be invaluable, as well as to the deployment of our web query portal as they look to centralize the management of a number of physically separate biobanks across their research enterprise.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GenoLogics Releases Clarity LIMS X as Part of Illumina SeqLab
Provides positive sample tracking, maximizes quality and throughput in population-scale genomics workflows.
Friday, July 31, 2015
GenoLogics Announces Expansion
Genomics informatics leader opens new office and bolsters hiring in response to demand for its products and services.
Saturday, February 28, 2015
GenomeDx Biosciences Implements Clarity LIMS for use in Clinical Lab
LIMS to support Decipher® Test for personalizing treatment for prostate cancer patients.
Wednesday, January 28, 2015
Frost & Sullivan Recognizes the High Value GenoLogics Offers its Customers
The superior quality Web interface and tool kits of the company’s LIMS solution have set an industry benchmark.
Wednesday, January 28, 2015
GenoLogics to Provide Illumina with LIMS for HiSeq X Ten System
GenoLogics has been selected by Illumina as the preferred laboratory information management system (LIMS) provider to support HiSeq X Ten sequencing system customers.
Thursday, September 04, 2014
GenoLogics Announces Availability of Clarity LIMS 3.1
New features bolster support for compliance in clinical environments.
Thursday, August 07, 2014
SciLifeLab Implements Genologics Clarity LIMS
One of Europe's largest genomics labs uses Clarity LIMS to support cutting edge sequencing services for Swedish researchers
Saturday, February 15, 2014
Personalis Selects Clarity LIMS, Citing Quick Deployment as Driver
Clarity LIMS User Base Growing
Tuesday, May 21, 2013
GenoLogics and Illumina Sign Deal
GenoLogics has signed a worldwide co-selling agreement with Illumina.
Wednesday, February 01, 2012
GenoLogics Raises $8 Million Strategic Financing Round Led by Illumina
Funds to accelerate product development and expand sales and marketing reach
Tuesday, December 27, 2011
EdgeBio Deploys the GenoLogics LIMS for Next-Generation Sequencing
LIMS is designed to provide the scalability, adaptability and usability features necessary for mainstream adoption of the most advanced sequencing technologies while supporting existing genotyping platforms
Tuesday, November 29, 2011
GenoLogics Releases White Paper on Increasing NGS Genomics Lab Throughput
GenoLogics has releases a white paper on how to improve lab efficiency and increase throughput with a pre-configured Laboratory Information Management System (LIMS)
Saturday, September 17, 2011
Enabling the USC Epigenome Center to keep up with Constantly Changing Next Generation Sequencing Technology and Rising Throughput
GenoLogics is enabling the USC Epigenome Center to accelerate their research, improve communications with customers and collaborators, while their lab scales with quickly changing genomics technologies and throughput.
Wednesday, November 17, 2010
University of Washington Selects New LIMS for Large-Scale Next Generation Sequencing Center
GenoLogics have announced that the University of Washington, Genome Sciences Genomics Resource Center (GS-GRC), has selected Geneus, the GenoLogics lab information and genomics data management system, for its next generation sequencing center.
Tuesday, November 16, 2010
University of Southern California Epigenome Center Chooses new System to Provide Next-Gen Data Management Solution
GenoLogics have announced that the Epigenome Center at the University of Southern California (USC) has purchased its lab and data management solution, Geneus, to manage its genomics and next generation sequencing data.
Tuesday, November 16, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos